| Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial T van der Vaart, E Plasschaert, AB Rietman, M Renard, R Oostenbrink, ... The Lancet Neurology 12 (11), 1076-1083, 2013 | 135 | 2013 |
| A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex IE Overwater, AB Rietman, SE Mous, K Bindels-de Heus, D Rizopoulos, ... Neurology 93 (2), e200-e209, 2019 | 90 | 2019 |
| HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1 A Omrani, T van der Vaart, E Mientjes, GM Van Woerden, MR Hojjati, ... Molecular psychiatry 20 (11), 1311-1321, 2015 | 75 | 2015 |
| Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues KA Rauen, SM Huson, E Burkitt‐Wright, DG Evans, S Farschtschi, ... American Journal of Medical Genetics Part A 167 (1), 1-10, 2015 | 56 | 2015 |
| Motor deficits in neurofibromatosis type 1 mice: the role of the cerebellum T van der Vaart, GM Van Woerden, Y Elgersma, CI De Zeeuw, ... Genes, Brain and Behavior 10 (4), 404-409, 2011 | 36 | 2011 |
| Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1 T van der Vaart, AB Rietman, E Plasschaert, E Legius, Y Elgersma, ... Neurology 86 (2), 154-160, 2016 | 34 | 2016 |
| Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models J Schreiber, LA Grimbergen, I Overwater, T Vaart, J Stedehouder, ... Scientific reports 7 (1), 1256, 2017 | 28 | 2017 |
| Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1 AB Rietman, T van der Vaart, E Plasschaert, BA Nicholson, R Oostenbrink, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 177 …, 2018 | 22 | 2018 |
| Update from the 2013 international neurofibromatosis conference SR Plotkin, AC Albers, D Babovic-Vuksanovic, JO Blakeley, ... American journal of medical genetics. Part A 164 (12), 2969, 2014 | 22 | 2014 |
| Treatment of cognitive deficits in genetic disorders: a systematic review of clinical trials of diet and drug treatments T van der Vaart, IE Overwater, R Oostenbrink, HA Moll, Y Elgersma JAMA neurology 72 (9), 1052-1060, 2015 | 15 | 2015 |
| ENCORE Expertise Centre for Neurodevelopmental Disorders. 2019. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex IE Overwater, AB Rietman, SE Mous, K Bindels-de Heus, D Rizopoulos, ... Neurology 93 (2), e200-e209, 0 | 6 | |
| OS07. 8. A Prognosis in IDH-mutant glioma: the role of extent-of-resection, age and tumor grade T Van der Vaart, MMJ Wijnenga, KA van Garderen, H Dubbink, PJ French, ... Neuro-oncology 24 (Suppl 2), ii17, 2022 | 2 | 2022 |
| Treatment of cognitive deficits in genetic disorders T Vaart, IE Overwater, R Oostenbrink, HA Moll, Y Elgersma JAMA Neurology 72 (9), 1052, 2015 | 2 | 2015 |
| A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups P Karschnia, M Smits, G Reifenberger, E Le Rhun, BM Ellingson, ... The Lancet Oncology 24 (11), e438-e450, 2023 | | 2023 |
| Author Reply to Walsh et al. HA Moll, T van der Vaart, A Rietman | | 2023 |
| P07. 11. A Impact of awake craniotomy on extent-of-resection and performance in glioma: a retrospective, propensity-score matched cohort study SJP Schnitzler, T van der Vaart, K van Garderen, MJ van den Bent, ... Neuro-Oncology 24 (Suppl 2), ii42, 2022 | | 2022 |
| Within-subject consistency of paired associative stimulation as assessed by linear mixed models MJ Ottenhoff, L Fani, NS Erler, J Castricum, IF Obdam, T der Vaart, ... bioRxiv, 434431, 2018 | | 2018 |
| BEHAVIORAL AND COGNITIVE OUTCOMES FOR CLINICAL TRIALS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 Response HA Moll, T van der Vaart, AB Rietman NEUROLOGY 86 (19), 1849-1850, 2016 | | 2016 |
| Translational research on targeted treatment for cognitive deficits in neurofibromatosis Type 1 T van der Vaart | | 2015 |
| The effect of lamotrigine on cognitive deficit in NF1: an update on the NF1-EXCEL trial MJ Ottenhoff, T Van der Vaart, AB Rietman, E Plasschaert, JHM Tulen, ... Abstract book, 8-8, 2015 | | 2015 |
Ype ElgersmaErasmus MC, Rotterdam, The NetherlandsVerified email at erasmusmc.nl
